Dr.Mateos shared trial design for MajesTEC-3: randomized, phase 3 study which will compare teclistamab plus daratumumab versus DPD or DVD in patients with relapsed/refractory multiple myeloma.
MajesTEC -1: trial results for teclistamab (a bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors) showed deep and durable responses in patients with highly refractory MM.
MagnetisMM-1: Clinical trial for elranatamab (BCMA-targeting bispecific antibody) showed an overall response rate of 54% in relapsed or refractory multiple myeloma.
Patients treated with newer immunotherapies have shown an emergence of infections like Pneumocystis jirovecii pneumonia (PJP) & CMV reactivation hence comprehensive infection management measures would be necessary for patients being treated with these therapies.
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
